US 12,187,662 B2
FOXM1 inhibitor compositions and methods of using the same
John A. Katzenellenbogen, Urbana, IL (US); Benita Katzenellenbogen, Urbana, IL (US); Sung Hoon Kim, Champaign, IL (US); and Noah Bindman, Seattle, WA (US)
Assigned to The Board of Trustees of the University of Illinois, Urbana, IL (US)
Appl. No. 17/046,161
Filed by The Board of Trustees of the University of Illinois, Urbana, IL (US)
PCT Filed Apr. 9, 2019, PCT No. PCT/US2019/026633
§ 371(c)(1), (2) Date Oct. 8, 2020,
PCT Pub. No. WO2019/199863, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/655,470, filed on Apr. 10, 2018.
Prior Publication US 2021/0032193 A1, Feb. 4, 2021
Int. Cl. C07C 217/18 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01)
CPC C07C 217/18 (2013.01) [A61P 35/00 (2018.01); G01N 33/57415 (2013.01)] 37 Claims
 
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein
G is an optionally substituted polycycloalkylidene;
RA and RB at each occurrence are independently halogen, C1-4alkyl, or C1-4haloalkyl;
R1 and R2 are independently —OH, halogen, —CN, —OC2-8alkylene-L-T, or —OR3, and at least one of R1 and R2 is —OR3;
L is a linker;
T is a fluorescence acceptor or a fluorescence donor;
R3 is —C4-8alkylene-NRxRy, —CH2CH2O—CH2CH2—NRxRy, or —(CH2CH2O)2—CH2CH2—NRxRy;
Rx and Ry at each occurrence are independently C1-4alkyl or —C2-4alkylene-OH, or
Rx and Ry together with the nitrogen to which they are attached form a 4- to 8-membered heterocycle or heteroaryl, wherein the heterocycle and heteroaryl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of C1-4alkyl, halogen, —OH, C1-4haloalkyl, and —C1-4alkylene-OH;
m is 0, 1, 2, 3, or 4; and
n is 0, 1, 2, 3, or 4.